Latest & greatest articles for amoxicillin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on amoxicillin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on amoxicillin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for amoxicillin

61. The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole

therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. Alimentary Pharmacology and Therapeutics 1999; 13(6): 719-729 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Adult; Amoxicillin /administration & Clarithromycin /administration & Drug Therapy, Combination; Enzyme Inhibitors /administration & Helicobacter Infections /drug therapy; Helicobacter pylori; Humans; Metronidazole /administration & Proton Pump Inhibitors; dosage; dosage; dosage; dosage (...) The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole The importance of clarithromycin dose in the management of Helicobacter pylori infection

1999 DARE.

62. Antimicrobial resistance and clinical effectiveness of co-trimoxazole versus amoxycillin for pneumonia among children in Pakistan: randomised controlled trial. Pakistan Co-trimoxazole Study Group. (Abstract)

Antimicrobial resistance and clinical effectiveness of co-trimoxazole versus amoxycillin for pneumonia among children in Pakistan: randomised controlled trial. Pakistan Co-trimoxazole Study Group. Co-trimoxazole is widely used in treatment of paediatric pneumonia in developing countries, but drug resistance may decrease its effectiveness. We studied the effectiveness of co-trimoxazole compared with that of amoxycillin in pneumonia therapy, and assessed the clinical impact of co-trimoxazole (...) resistance.We recruited 595 children, aged 2-59 months, with non-severe or severe pneumonia (WHO criteria) diagnosed in the outpatient wards of two urban Pakistan hospitals. Patients were randomly assigned on a 2:1 basis co-trimoxazole (n=398) or amoxycillin (n=197) in standard WHO doses and dosing schedules, and were monitored in study wards. The primary outcome was inpatient therapy failure (clinical criteria) or clinical evidence of pneumonia at outpatient follow-up examination.There were 92 (23

1998 Lancet Controlled trial quality: uncertain

63. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. Full Text available with Trip Pro

Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. It is uncertain whether treatment of Helicobacter pylori infection relieves symptoms in patients with nonulcer, or functional, dyspepsia.We conducted a double-blind, multicenter trial of patients with H. pylori infection and dyspeptic symptoms (moderate-to-very-severe pain and discomfort centered (...) in the upper abdomen). Patients were excluded if they had a history of peptic ulcer disease or gastroesophageal reflux disease and had abnormal findings on upper endoscopy. Patients were randomly assigned to seven days of treatment with 20 mg of omeprazole twice daily, 1000 mg of amoxicillin twice daily, and 500 mg of clarithromycin twice daily or with omeprazole alone and then followed up for one year. Treatment success was defined as the absence of dyspeptic symptoms or the presence of minimal symptoms

1998 NEJM Controlled trial quality: predicted high

64. Elective penicillin skin testing and amoxicillin challenge: effect on outpatient antibiotic use, cost, and clinical outcomes

Elective penicillin skin testing and amoxicillin challenge: effect on outpatient antibiotic use, cost, and clinical outcomes Elective penicillin skin testing and amoxicillin challenge: effect on outpatient antibiotic use, cost, and clinical outcomes Elective penicillin skin testing and amoxicillin challenge: effect on outpatient antibiotic use, cost, and clinical outcomes Macy E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Elective penicillin skin testing (PenSTs) in advance of acute antibiotic need and (optional) amoxicillin challenge (AC) in patients with negative skin test responses. Patients were previously entered in a study of new penicillin reagents and received at least 1 prescription drug over a 2-year period

1998 NHS Economic Evaluation Database.

65. Are amoxycillin and folate inhibitors as effective as other antibiotics for acute sinusitis: a meta-analysis

C. Review: amoxycillin and folate inhibitors are as effective as newer more expensive antibiotics for acute sinusitis. Evid Based Med 1999;4:77. Antibiotics for acute sinusitis in general practice [letters]. BMJ 1999;318:1623-4. Indexing Status Subject indexing assigned by NLM MeSH Acute Disease; Amoxicillin /therapeutic use; Anti-Bacterial Agents /therapeutic use; Folic Acid Antagonists /therapeutic use; Humans; Penicillins /therapeutic use; Quality Control; Randomized Controlled Trials (...) Are amoxycillin and folate inhibitors as effective as other antibiotics for acute sinusitis: a meta-analysis Are amoxycillin and folate inhibitors as effective as other antibiotics for acute sinusitis: a meta-analysis Are amoxycillin and folate inhibitors as effective as other antibiotics for acute sinusitis: a meta-analysis de Ferranti S D, Ioannidis J P, Lau J, Anninger W V, Barza M Authors' objectives To examine whether antibiotics are indicated in treating uncomplicated acute sinusitis

1998 DARE.

66. Randomised, double blind, placebo controlled trial of penicillin V and amoxycillin in treatment of acute sinus infections in adults. Full Text available with Trip Pro

Randomised, double blind, placebo controlled trial of penicillin V and amoxycillin in treatment of acute sinus infections in adults. To compare the effectiveness of penicillin V and amoxycillin with placebo in treatment of adult patients with acute sinusitis.Randomised, double blind, placebo controlled trial.Norwegian general practice.130 adult patients with a clinical diagnosis of acute sinusitis confirmed by computed tomography.Subjective status after three and 10 days of treatment (...) severity scores by day 10 were 5.4 (5.0 to 5.8) for penicillin V, 5.5 (4.9 to 6.0 for amoxycillin, and 3.4 (2.8 to 4.0) for placebo. For the antibiotic groups combined the number of patients with the greatest degree of improvement on computed tomography (scale 0-16)-that is, score 5-16 on day 10-was 31/83 (37%) compared with 10/44 (23%) receiving placebo. The median duration of the sinusitis was nine days in the amoxycillin group, 11 days in the penicillin V group, and 17 days in the placebo

1996 BMJ Controlled trial quality: predicted high

67. Decision analysis of Helicobacter pylori eradication therapy using omeprazole with either clarithromycin or amoxicillin

Decision analysis of Helicobacter pylori eradication therapy using omeprazole with either clarithromycin or amoxicillin Decision analysis of Helicobacter pylori eradication therapy using omeprazole with either clarithromycin or amoxicillin Decision analysis of Helicobacter pylori eradication therapy using omeprazole with either clarithromycin or amoxicillin Craig A M, Davey P, Malek M, Murray F Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Helicobacter pylori eradication therapy using omeprazole with either clarithromycin or amoxicillin. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The analysis was carried out for three distinct patient groups: patients with proven

1996 NHS Economic Evaluation Database.

68. Pharmacoeconomic evaluation of roxithromycin versus amoxycillin clavulanic acid in a community-acquired lower respiratory tract infection study

. versus Amoxycillin 500mg/clavulanic acid 125 mg t.i.d. for the treatment oflower respiratory tract infections in general practice. Infection 1995;23(Supplement 1):S15-S20. Indexing Status Subject indexing assigned by NLM MeSH Adolescent; Adult; Aged; Amoxicillin /economics /therapeutic use; Amoxicillin-Potassium Clavulanate Combination; Clavulanic Acids /economics /therapeutic use; Cost-Benefit Analysis; Drug Therapy, Combination /therapeutic use; Female; Humans; Male; Middle Aged; Respiratory Tract (...) Pharmacoeconomic evaluation of roxithromycin versus amoxycillin clavulanic acid in a community-acquired lower respiratory tract infection study Pharmacoeconomic evaluation of roxithromycin versus amoxycillin clavulanic acid in a community-acquired lower respiratory tract infection study Pharmacoeconomic evaluation of roxithromycin versus amoxycillin clavulanic acid in a community-acquired lower respiratory tract infection study Scott W G, Cooper B C, Scott H M Record Status This is a critical

1995 NHS Economic Evaluation Database.

69. Amoxicillin or erythromycin for the treatment of antenatal chlamydial infection: a meta-analysis

Amoxicillin or erythromycin for the treatment of antenatal chlamydial infection: a meta-analysis Amoxicillin or erythromycin for the treatment of antenatal chlamydial infection: a meta-analysis Amoxicillin or erythromycin for the treatment of antenatal chlamydial infection: a meta-analysis Turrentine M A, Newton E R Authors' objectives To compare the effectiveness of amoxicillin and erythromycin for the treatment of antenatal Chlamydia trachomatis infection. Searching MEDLINE and the Cochrane (...) Pregnancy and Childbirth Database were searched for English language abstracts using the MeSH 'pregnancy', 'chlamydia', 'erythromycin', 'amoxicillin', 'antenatal' and 'antibiotics'). Bibliographies of identified articles were also examined. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) were included. Specific interventions included in the review Oral amoxicillin (500 mg three times daily for 7 days) or erythromycin (500 mg four times daily for 7

1995 DARE.

70. The cost effectiveness of amoxicillin/clavulanic acid as antibacterial prophylaxis in abdominal and gynaecological surgery

The cost effectiveness of amoxicillin/clavulanic acid as antibacterial prophylaxis in abdominal and gynaecological surgery The cost effectiveness of amoxicillin/clavulanic acid as antibacterial prophylaxis in abdominal and gynaecological surgery The cost effectiveness of amoxicillin/clavulanic acid as antibacterial prophylaxis in abdominal and gynaecological surgery Davey P G, Parker S E, Crombie I K, Jaderberg M Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Use of amoxicillin/clavulanic acid (ACA) as antibacterial prophylaxis in abdominal and gynaecological surgery. Type of intervention Prophylaxis. Economic study type Cost-effectiveness analysis. Study population Patients undergoing abdominal and gynaecological surgery

1995 NHS Economic Evaluation Database.

71. Randomised comparison of amoxycillin and erythromycin in treatment of genital chlamydial infection in pregnancy. (Abstract)

Randomised comparison of amoxycillin and erythromycin in treatment of genital chlamydial infection in pregnancy. Erythromycin, the standard treatment for chlamydial infection in pregnant women, commonly causes side-effects, which limits its efficacy. In a randomised, double-blind study, we compared amoxycillin with erythromycin in this setting. 210 pregnant women with Chlamydia trachomatis infection were randomly assigned 7 days' treatment with amoxycillin (500 mg three times daily (...) ) or erythromycin (500 mg four times daily). Control cultures were obtained 21 days after treatment, during late pregnancy, and from the infant within a week of birth. Treatment was judged a failure if any post-treatment culture was positive or if the patient had to stop therapy because of severe side-effects. 11 women (5.2%) were lost to follow-up. 1 (of 100) amoxycillin-treated women had to stop treatment because of severe side-effects compared with 12 (of 99) erythromycin-treated women (p = 0.002). 1 woman

1994 Lancet Controlled trial quality: uncertain

72. A pharmacoeconomic comparison of amoxicillin/clavulanate and cefpodoxime proxetil in the treatment of acute otitis media

A pharmacoeconomic comparison of amoxicillin/clavulanate and cefpodoxime proxetil in the treatment of acute otitis media A pharmacoeconomic comparison of amoxicillin/clavulanate and cefpodoxime proxetil in the treatment of acute otitis media A pharmacoeconomic comparison of amoxicillin/clavulanate and cefpodoxime proxetil in the treatment of acute otitis media Landholt T F, Kotschwar T R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Treatment of acute otitis media in children with amoxicillin/ clavulanate potassium or cefpodoxime proxetil. Type of intervention Treatment Economic study type Cost-effectiveness analysis. Study population Children (males and females) were divided equally into two groups with an average

1994 NHS Economic Evaluation Database.

73. A clinical and economic comparison of roxithromycin 150 mg twice daily vs amoxicillin 500mg/calvulanic acid 125mg three times daily for the treatment of lower respiratory tract infections in general practice

A clinical and economic comparison of roxithromycin 150 mg twice daily vs amoxicillin 500mg/calvulanic acid 125mg three times daily for the treatment of lower respiratory tract infections in general practice A clinical and economic comparison of roxithromycin 150 mg twice daily vs amoxicillin 500mg/calvulanic acid 125mg three times daily for the treatment of lower respiratory tract infections in general practice A clinical and economic comparison of roxithromycin 150 mg twice daily vs (...) amoxicillin 500mg/calvulanic acid 125mg three times daily for the treatment of lower respiratory tract infections in general practice Karalus N C, Garrett J E, Lang S D, Scott W G, Leng R A, Kostalas G N, Cursons R T, Cooper B C, Scott H M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability

1994 NHS Economic Evaluation Database.

74. Treatment of streptococcal pharyngitis with amoxycillin once a day. Full Text available with Trip Pro

Treatment of streptococcal pharyngitis with amoxycillin once a day. To evaluate treatment of group A beta haemolytic streptococcal pharyngitis with amoxycillin once daily compared with phenoxymethylpenicillin three or four times a day.Randomised controlled study of consecutive patients presenting with symptoms suggestive of group A beta haemolytic streptococcal pharyngitis in whom culture of a throat swab yielded positive results.Five family medicine practices.157 patients aged over 3 years who (...) required treatment with antibiotics.Clinical response, bacteriological response, days at work and school lost, and compliance.During the period of the study 393 patients presented with symptoms suggesting streptococcal pharyngitis; 157 of them had throat swabs that yielded positive results on culture. Eighty two were treated with phenoxymethylpenicillin and 75 with amoxycillin. No difference was observed in the clinical response, days at work and school lost (139 days for 64 patients taking

1993 BMJ Controlled trial quality: uncertain

75. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. (Abstract)

Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. Persistent infection with Helicobacter pylori is associated with the recurrence of duodenal ulcer. Whether the efficacy of bismuth therapy in reducing the rate of recurrence of duodenal ulcer is due to its antimicrobial effects on H. pylori or to a direct protective action on the mucosa is still a matter of debate.To study the effect of the eradication of H (...) . pylori on the recurrence of duodenal ulcer, we treated 104 patients with H. pylori infection and recurrent duodenal ulcer with either amoxicillin (750 mg three times daily) plus metronidazole (500 mg three times daily) or identical-appearing placebos, given orally for 12 days. All patients also received ranitidine (300 mg each night) for 6 or 10 weeks. Endoscopy was performed before treatment and periodically during follow-up for up to 12 months after healing.Among the 52 patients given antibiotics

1993 NEJM Controlled trial quality: uncertain

76. Amoxycillin plus probenecid versus doxycycline for treatment of erythema migrans borreliosis. (Abstract)

Amoxycillin plus probenecid versus doxycycline for treatment of erythema migrans borreliosis. 72 adults with erythema migrans (early Lyme borreliosis) were enrolled in a randomised prospective trial comparing amoxycillin 500 mg plus probenecid 500 mg three times a day with doxycycline 100 mg twice a day for 21 days. These antibiotic regimens were chosen because of the known in-vitro sensitivity of Borrelia burgdorferi, the antibiotic tissue penetration, the pharmacokinetics of the drugs (...) , and because the organism can disseminate early in the course of infection. 72 patients were evaluable (35 in the doxycycline group and 37 in the amoxycillin/probenecid group). The two regimens were equally effective for treatment of erythema migrans. Mild fatigue or arthralgia were the only post-treatment complaints, which resolved within 6 months. None of the patients needed further antibiotic treatment for Lyme borreliosis.

1990 Lancet Controlled trial quality: uncertain

77. Randomised study of myringotomy, amoxycillin/clavulanate, or both for acute otitis media in infants. (Abstract)

Randomised study of myringotomy, amoxycillin/clavulanate, or both for acute otitis media in infants. In a prospective study, 105 infants aged 3-12 months with acute otitis media were randomly assigned to one of three treatment groups: amoxycillin/clavulanate ('Augmentin') alone (36 patients), myringotomy plus placebo (35 patients), or augmentin plus myringotomy (34 patients). The last two groups were double-blinded. Bacterial pathogens, mainly Haemophilus influenzae (of which 20% were beta

1989 Lancet Controlled trial quality: uncertain

78. Efficacy of amoxicillin with and without decongestant-antihistamine for otitis media with effusion in children. Results of a double-blind, randomized trial. Full Text available with Trip Pro

Efficacy of amoxicillin with and without decongestant-antihistamine for otitis media with effusion in children. Results of a double-blind, randomized trial. In a randomized, double-blind, placebo-controlled trial involving 518 infants and children who had otitis media with effusion ("secretory" otitis media), we evaluated the efficacy of a two-week course of amoxicillin (40 mg per kilogram of body weight per day) with and without a four-week course of an oral decongestant-antihistamine (...) combination. Among the 474 subjects who were evaluated at the four-week end point, the rate of resolution of middle-ear effusion was twice as high in those treated with amoxicillin, either with or without the decongestant-antihistamine, as in those who received placebo (P less than 0.001), but 69.8 percent of the amoxicillin-treated subjects still had effusion. Among both the amoxicillin-treated subjects and the placebo-treated subjects, resolution was more likely in those with initially unilateral

1987 NEJM Controlled trial quality: predicted high

79. Single-dose therapy for cystitis in women. A comparison of trimethoprim-sulfamethoxazole, amoxicillin, and cyclacillin. (Abstract)

Single-dose therapy for cystitis in women. A comparison of trimethoprim-sulfamethoxazole, amoxicillin, and cyclacillin. We evaluated single-dose regimens of trimethoprim-sulfamethoxazole, amoxicillin, and cyclacillin as treatment for acute cystitis in 38 women. The trial was prematurely stopped because of frequent treatment failures. At two days after treatment, all 13 patients given trimethoprim-sulfamethoxazole were cured, while four (31%) of 13 given amoxicillin and four (33%) of 12 given (...) cyclacillin had persistent bacteriuria. At two weeks, 11 (85%) of 13 patients given trimethoprim-sulfamethoxazole, six (50%) of 12 given amoxicillin, and three (30%) of ten given cyclacillin were cured. One patient with positive results of antibody-coated bacteria testing who was treated with cyclacillin had signs and symptoms of acute pyelonephritis three days after treatment, and two patients treated with amoxicillin and one treated with trimethoprim-sulfamethoxazole converted antibody-coated bacteria

1985 JAMA

80. Double-blind study to compare the selection of antibiotic resistance by amoxycillin or cephradine in the commensal flora. (Abstract)

Double-blind study to compare the selection of antibiotic resistance by amoxycillin or cephradine in the commensal flora. Elderly patients with acute urinary infections were treated in a double-blind study with either amoxycillin or cephradine. In 52 patients who had received amoxycillin for one week about a third of all intestinal Escherichia coli were highly resistant to amoxycillin, and many were resistant to tetracycline, trimethoprim, or chloramphenicol. Cephradine selected less resistance (...) . At a week after completion of chemotherapy, cephradine-resistant E coli were replaced by sensitive cultures at a greater frequency than were amoxycillin-resistant E coli. Neither antibiotic altered the skin flora. Amoxycillin, but not cephradine, selected for Enterobacteriaceae in the saliva. The propensity of amoxycillin to select resistance in E coli will limit its usefulness in treating urinary infections.

1983 Lancet Controlled trial quality: uncertain